年轻重度血脂异常患者他汀处方率
该研究旨在评估在真实世界中筛查出血脂异常的患者他汀处方率,以识别治疗差距。研究对象为接受血脂异常筛查的患者,重点关注LDL-C≥190 mg/dL的年轻患者。原文指出他汀治疗推荐用于所有LDL-C≥190 mg/dL的21岁以上成人(class IA)。
要点
- LDL-C≥190 mg/dL可能提示单基因病因如家族性高胆固醇血症。
- 他汀治疗推荐用于所有LDL-C≥190 mg/dL的21岁以上成人(class IA)。
- 研究旨在检查真实世界筛查人群中他汀处方率以识别治疗差距。
核心结论
- 研究旨在检查真实世界筛查人群中他汀处方率以识别治疗差距。
研究设计与样本
- 研究设计为检查接受血脂异常筛查患者的他汀处方率,样本量原文未报告。
主要发现
- 原文未报告具体研究结果数值。
关键数值与推荐
- 他汀治疗推荐用于所有LDL-C≥190 mg/dL的21岁以上成人(class IA)。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiovascular disease affects 1 in 3 patients and remains the leading cause of death in the United States. Severe elevation of low-density lipoprotein cholesterol (LDL-C) levels is a modifiable risk factor for developing premature cardiovascular disease, and elevation levels of 190 mg/dL or greater (to convert LDL-C values to millimoles per liter, multiply by 0.0259) may indicate a monogenic etiology such as familial hypercholesterolemia. Treatment with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins is recommended (class IA) for all adults 21 years or older with an LDL-C of 190 mg/dL or greater. Statin treatment appears to reduce mortality and result in cost savings for health systems., Therefore, we sought to examine rates of statin prescription in patients screened for dyslipidemia to identify treatment gaps in a real-world contemporary setting.
引用
- Al-Kindi SG, DeCicco A, Longenecker CT, et al. Rate of Statin Prescription in Younger Patients With Severe Dyslipidemia. JAMA Cardiol. 2017. PMID: 28052161. doi:10.1001/jamacardio.2016.5162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。